Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.InSight Health sells imaging center to RadNet
Kip Hallman, president and CEO of InSight Health, said: “With the sale of this final center, we have now exited the San Fernando Valley, which was a non-core
Kip Hallman, president and CEO of InSight Health, said: “With the sale of this final center, we have now exited the San Fernando Valley, which was a non-core
The alliance will provide Allarae with access to an established global distribution channel for immediate sale of its products and services in about 30 countries outside the US,
This move is expected to create 300 jobs over the next three years. The types of jobs created by DocuSys will range from software engineering, software implementation and
The strategic alliance, initiated in June 2001, included an initial five-year research term and has been extended on two prior occasions, in each case with the objective to
Under the terms of the agreement, research targets will be determined by a steering committee composed of leading scientists at University of California, San Francisco (UCSF), including Lewis
Under the terms of the research period extension, Wyeth’s obligations to Trubion include collaboration research funding commitments of approximately $3.2 million in exchange for committed research services through
With the acquisition process underway, both Intas Biopharma and Biologics Process Development (BPD) are actively pursuing plans to work closely toward fulfillment of common business objectives in the
The final report on this randomized, double-blinded, vehicle-controlled study to evaluate the safety, tolerability and efficacy of topically applied WBI-1001 cream in subjects with atopic dermatitis is expected
The blood-based test would be designed to look for certain markers for the cancers potentially allowing for early detection of these cancers as well as assisting the selection
The FDA approval was based on two-year results of the CombAT study, one of the largest clinical trials to date of men with enlarged prostate. The CombAT study